Gabriel-Cromwell aziridination of amino sugars; chiral ferrocenoyl-aziridinyl sugar synthesis and their biological evaluation

N-sugar substituted chiral aziridines were synthesized via Gabriel-Cromwell reaction. Novel pure diastereomers of aziridine derivatives (4 diastereomers) were readily obtained in high yields and their structures were confirmed by means of 1H NMR, 13C NMR, FT-IR, Mass and optical rotations. This is,...

Full description

Saved in:
Bibliographic Details
Published inCarbohydrate research Vol. 509; pp. 108430 - 108437
Main Authors Sert, Mustafa, Işılar, Özer, Yaglioglu, Ayse Sahin, Bulut, Adnan
Format Journal Article
LanguageEnglish
Published OXFORD Elsevier Ltd 01.11.2021
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:N-sugar substituted chiral aziridines were synthesized via Gabriel-Cromwell reaction. Novel pure diastereomers of aziridine derivatives (4 diastereomers) were readily obtained in high yields and their structures were confirmed by means of 1H NMR, 13C NMR, FT-IR, Mass and optical rotations. This is, to the best of our knowledge, the unique example of N-sugar aziridine synthesis. Diastereomeric effects for prostate (PC3) and cervix (HeLa) cancers were screened and it has been observed that the epimers bearing the same sugars showed different results against PC3 and HeLa cancer cells. The novel sugar aziridines were investigated as promising prodrug candidates for prostate cancer (PC3) therapy. Moreover, the drug likeness calculations (Lipinski's rule, physicochemical properties, lipophilicity, solubility, pharmacokinetics and bioavailability radar) have indicated that the sugar aziridines can be good candidates as oral drugs. [Display omitted] •Aziridinyl sugars were synthesized for the first time by the Gabriel-Cromwell reaction.•Ferrocene-containing aziridinyl sugar diastereomers were easily separated from each other by flash column chromatography.•Ferrocene-Aziridine-Sugar diastereomers are promising prodrug candidates for prostate cancer (PC3) therapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0008-6215
1873-426X
1873-426X
DOI:10.1016/j.carres.2021.108430